Atossa Therapeutics (ATOS) Operating Income (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Operating Income of -$9.9 million for Q1 2026, down 33.13% year-over-year from -$14.8 million in Q1 2025, and up 13.69% quarter-over-quarter from -$11.4 million in Q4 2025.
Atossa Therapeutics (ATOS) Operating Income (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Operating Income for 16 consecutive years, with -$9.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 33.13% year-over-year to -$9.9 million; the TTM figure through Mar 2026 stood at -$39.6 million (down 41.14% YoY), while the FY2025 annual figure was -$37.1 million, down 34.47% from the prior year.
- Operating Income improved to -$9.9 million in Q1 2026 per ATOS's latest filing, from -$11.4 million in the prior quarter.
- Across five years, Operating Income topped out at -$4.7 million in Q1 2022 and bottomed at -$11.4 million in Q4 2025.
- Historically, Operating Income has averaged -$7.9 million across 5 years, with a median of -$7.5 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Income sank 68.56% — and 2024, when it climbed 20.71%.
- Atossa Therapeutics' Operating Income stood at -$8.1 million in 2022, then dropped by 10.83% to -$9.0 million in 2023, then increased by 20.71% to -$7.2 million in 2024, then tumbled by 59.92% to -$11.4 million in 2025, then advanced by 13.69% to -$9.9 million in 2026.
- Business Quant data shows ATOS's Operating Income at -$9.9 million in Q1 2026, -$11.4 million in Q4 2025, and -$9.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 133.12 Mn |
| 10 | Atossa Therapeutics | 23.07 Mn | 23.07 Mn | - | -8.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.69 Mn |
| Mar 31, 2026 | -9.87 Mn |
| Dec 31, 2025 | -11.44 Mn |
| Sep 30, 2025 | -9.25 Mn |
| Jun 30, 2025 | -9.04 Mn |
| Mar 31, 2025 | -7.41 Mn |
| Dec 31, 2024 | -7.15 Mn |
| Sep 30, 2024 | -6.39 Mn |
| Jun 30, 2024 | -7.11 Mn |
| Mar 31, 2024 | -6.98 Mn |
| Dec 31, 2023 | -9.02 Mn |
| Sep 30, 2023 | -7.47 Mn |
| Jun 30, 2023 | -7.79 Mn |
| Mar 31, 2023 | -7.10 Mn |
| Dec 31, 2022 | -8.14 Mn |
| Sep 30, 2022 | -8.21 Mn |
| Jun 30, 2022 | -6.60 Mn |
| Mar 31, 2022 | -4.75 Mn |
| Dec 31, 2021 | -4.83 Mn |
| Sep 30, 2021 | -5.16 Mn |